Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer.

@article{Spigel2012TreatmentRS,
  title={Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer.},
  author={David Robert Spigel and Martin J. Edelman and Tony C. W. Mok and Kenneth J O'byrne and Luis Paz-Ares and Wei Yu and Karen Rittweger and Holger Thurm},
  journal={Clinical lung cancer},
  year={2012},
  volume={13 6},
  pages={500-4}
}
We present the treatment rationale and study design of the MetLung phase III study. This study will investigate onartuzumab (MetMAb) in combination with erlotinib compared with erlotinib alone, as second- or third-line treatment, in patients with advanced non-small-cell lung cancer (NSCLC) who are Met-positive by immunohistochemistry. Approximately 490 patients (245 per treatment arm) will receive erlotinib (150 mg oral daily) plus onartuzumab or placebo (15 mg/kg intravenous every 3 weeks… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

Regulation of Signal Transduction in Human Cell Research

Current Human Cell Research and Applications • 2018

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Erlotinib in previously treated non-small-cell lung cancer.

The New England journal of medicine • 2005
View 8 Excerpts
Highly Influenced

Efficacy and safety of erlotinib versus chemotherapy in second-line, advanced, non-small-cell lung cancer (NSCLC) with poor prognosis: the phase 3 randomised Titan study

T Ciuleanu, L Stelmakh, S Cicenas
Lancet Oncol • 2012
View 1 Excerpt

published erratum appears in: CA

A Jemal, R Siegel, J Xu
Cancer statistics, • 2010
View 1 Excerpt

Group

NSCLC Meta-Analyses Collaborativ
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol • 2008
View 1 Excerpt

Signaling networks assembled by oncogenic EGFR and c-Met.

Proceedings of the National Academy of Sciences of the United States of America • 2008

Similar Papers

Loading similar papers…